Bryce Mander, PhD
Bryce Mander, PhD
Dr. Bryce Mander is an Associate Professor in the Departments of Psychiatry and Human Behavior, Pathology and Laboratory Medicine, and Cognitive Sciences at University of California, Irvine. He is a faculty member of the Institute for Memory Impairments and Neurological Disorders and the Centers for Aging Research in Down Syndrome and Sleep and Circadian Neuroscience, as well as a faculty fellow of the Center for the Neurobiology of Learning and Memory. Dr. Mander’s research utilizes a multimodal neuroimaging approach to examine relationships between sleep physiology, cognitive aging, and dementia pathophysiology. His research program aims to characterize how and when sleep interacts with neurodegenerative pathophysiology and medical disorders to impact dementia.
He received his PhD in Neuroscience from Northwestern University and completed his postdoctoral fellowship at the University of California, Berkeley.
Lennart Mucke, PhD
Lennart Mucke, PhD
As founding director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco, Dr. Mucke has developed a premier program for research and training in disease-focused neuroscience. He has unravelled pathophysiological mechanisms of cognitive decline in Alzheimer's disease (AD) and identified unexpected links among AD, epilepsy and autism spectrum disorders, as well as related entry points for novel interventions that could be of therapeutic benefit in multiple neurological and psychiatric conditions. Dr. Mucke is an elected member of the U.S. National Academy of Medicine and has received the Potamkin Prize, MetLife Foundation Award for Medical Research, and Khalid Iqbal Lifetime Achievement Award. He has served on the National Advisory Council on Aging for the U.S. National Institutes of Health and has chaired the Senate of the German Center for Neurodegenerative Diseases.
Biophysical Chemistry in Göttingen, Cleveland Clinic, Massachusetts General Hospital, Harvard Medical School, and The Scripps Research Institute.
Shane Liddelow, PhD
Academic Co-Founder
Shane Liddelow, PhD
Academic Co-Founder
Dr. Shane Liddelow is an expert in astrocyte biology and neuroinflammation, actively contributing to the field for over a decade. His research includes the discovery of neurotoxic reactive astrocytes, which are significant in understanding conditions like Alzheimer’s and Parkinson’s. Currently an Associate Professor at NYU Grossman School of Medicine in New York, Dr. Liddelow’s lab focuses on glial cell interactions and their impact on neurodegenerative diseases.
His research discoveries are among the most highly cited in the field, and his lab continues to discover novel substates of reactive astrocytes that are implicated in neurodegenerative disease. His expertise and innovative approach have earned him prestigious accolades, making him a leading figure in the fight against neurodegeneration.
Shane gained his Bachelor of Science (Hons) and Biomedical Science from the University of Melbourne, Australia, majoring in Neuroscience and Anatomy & Cell Biology. He received his PhD with Katarzyna Dziegielewska and Norman Saunders in Pharmacology also from the University of Melbourne.
Giles Hardingham, PhD, FRSE FMedsci
Academic Co-Founder
Giles Hardingham, PhD, FRSE FMedsci
Academic Co-Founder
Professor Giles Hardingham FRSE FMedsci established his laboratory at the University of Edinburgh in 2002 as a Royal Society University Research Fellow, moving onto a MRC Senior Non-Clinical Research Fellowship in 2010. In 2017 he was elected to the City of Edinburgh Chair of Pharmacology and became founding Director of the Edinburgh Centre of the UK Dementia Research Institute, which has a membership of 150 researchers.
He is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences, and his research is focussed on understanding signaling within and between cells in the brain. His aim is to characterise the inter-cellular interactions that maintain brain homeostasis when we are healthy, and how these mechanisms break down in diseases that cause dementia.
He studied Natural Sciences at the University of Cambridge before completing a PhD at the MRC Laboratory of Molecular Biology.
Paul Whiting, PhD
Academic Co-Founder
Paul Whiting, PhD
Academic Co-Founder
Paul is an experienced academic and pharmaceutical industry scientist with expertise in neuropsychiatric and neurodegenerative disorders. He has had senior leadership roles at both Merck Sharp & Dohme and Pfizer, and more recently as Professor at Queen Square Institute of Neurology at UCL/Chief Scientific Officer (CSO) for the Alzheimer’s Research UK UCL Drug Discovery Institute (UCL-DDI). He is a co-founder of AstronauTx Ltd.
Paul’s scientific contributions span from ion channel neurobiology, the biology of schizophrenia, pluripotent stem cell disease modelling through to neurodegenerative diseases, with over 250 scientific publications. He is currently co-lead of the UCL Neurogenetic Therapies Programme, a portfolio of preclinical and clinical projects using ASO/viral overexpression/CRISPR approaches for neurodegenerative diseases.
Paul obtained a first-class honours degree from the University of Leeds, followed by a PhD at the University of London. He moved to the Salk Institute for Biological Studies in San Diego for his postdoc.
